Management of cancer-associated thrombosis is in a state of flux with guidelines still mostly recommending low molecular weight heparin (LMWH) but more recent trials and clinicians leaning towards novel oral anticoagulants (NOACs). Speaking at Blood 2018, Professor Saskia Middledorp, co-chair of vascular medicine at the Academic Medical Centre in The Netherlands, called for some caution in ...
It’s too early to embrace NOACs for all patients with cancer
By Mardi Chapman
31 Oct 2018